ESPR Quote, Financials, Valuation and Earnings

Harrow, Inc. has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of 7.44%. Esperion Therapeutics, Inc.'s return on equity of -- beat Harrow, Inc.'s return on equity of -9.4%.

Esperion Therapeutics, Inc. has a consensus price target of $6.99, signalling upside risk potential of 167.87%. On the other hand Harrow, Inc. has an analysts' consensus of $69.38 which suggests that it could grow by 96.47%. Given that Esperion Therapeutics, Inc. has higher upside potential than Harrow, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Harrow, Inc..

Esperion Therapeutics, Inc. has a beta of 1.174, which suggesting that the stock is 17.374% more volatile than S&P 500. In comparison Harrow, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.038%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Harrow, Inc. pays out -- of its earnings as a dividend.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are larger than Harrow, Inc. quarterly revenues of $89.1M. Esperion Therapeutics, Inc.'s net income of $61.8M is higher than Harrow, Inc.'s net income of $6.6M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Harrow, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.43x versus 4.87x for Harrow, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of -165.45%. Esperion Therapeutics, Inc.'s return on equity of -- beat Nektar Therapeutics's return on equity of -364.32%.

Esperion Therapeutics, Inc. has a consensus price target of $6.99, signalling upside risk potential of 167.87%. On the other hand Nektar Therapeutics has an analysts' consensus of $128.13 which suggests that it could grow by 66.42%. Given that Esperion Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Esperion Therapeutics, Inc. is more attractive than Nektar Therapeutics.

Esperion Therapeutics, Inc. has a beta of 1.174, which suggesting that the stock is 17.374% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.165, suggesting its more volatile than the S&P 500 by 16.45%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are larger than Nektar Therapeutics quarterly revenues of $21.8M. Esperion Therapeutics, Inc.'s net income of $61.8M is higher than Nektar Therapeutics's net income of -$36.1M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.43x versus 93.68x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of 21.74%. Esperion Therapeutics, Inc.'s return on equity of -- beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Esperion Therapeutics, Inc. has a consensus price target of $6.99, signalling upside risk potential of 167.87%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.70 which suggests that it could grow by 14.55%. Given that Esperion Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Esperion Therapeutics, Inc. has a beta of 1.174, which suggesting that the stock is 17.374% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.238%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.94 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Esperion Therapeutics, Inc.'s net income of $61.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.43x versus 5.66x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 36.71% compared to Esperion Therapeutics, Inc.'s net margin of 40.17%. Esperion Therapeutics, Inc.'s return on equity of -- beat Rigel Pharmaceuticals, Inc.'s return on equity of 299.43%.

Esperion Therapeutics, Inc. has a consensus price target of $6.99, signalling upside risk potential of 167.87%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.20 which suggests that it could grow by 85.98%. Given that Esperion Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Esperion Therapeutics, Inc. has a beta of 1.174, which suggesting that the stock is 17.374% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.172%.

Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Esperion Therapeutics, Inc. quarterly revenues are $168.4M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.8M. Esperion Therapeutics, Inc.'s net income of $61.8M is lower than Rigel Pharmaceuticals, Inc.'s net income of $268.1M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 1.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 1.43x versus 1.77x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.